Competition is high, and a few stemcell companies have pivoted into exosomes.
What makes EX1 different though is that they are creating the pickaxes of actually creating the exosomes. Others will be the miners and make them into useful biologics. EX1 is helping to do that with their studies, but I think it is a play to make the space bigger for them supplying everyone with the exosomes.
- Forums
- ASX - By Stock
- TYP
- Buy Recommendation
Buy Recommendation, page-70
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TYP (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $22.87M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.1¢ | $4.354K | 203.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 1202944 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 104 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 1202944 | 0.020 |
8 | 1307398 | 0.019 |
5 | 682509 | 0.018 |
1 | 500000 | 0.017 |
3 | 1058231 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 104 | 1 |
0.022 | 930652 | 3 |
0.023 | 403477 | 3 |
0.024 | 40529 | 1 |
0.025 | 721144 | 4 |
Last trade - 10.15am 03/09/2024 (20 minute delay) ? |
Featured News
TYP (ASX) Chart |